Project Grant HT94252310944

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $269,942 to Baystate Medical Center, Inc. to develop and pilot test a community health worker (CHW) intervention to improve lung cancer screening (LCS) uptake among Black and Hispanic communities served by community health centers. The key objectives are to: 1) jointly "transcreate" the CHW intervention with a community advisory board, 2) conduct a pilot randomized controlled...

This $968,999 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a research study titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The study aims to optimize post-treatment surveillance for lung cancer survivors by incorporating risk-based strategies that leverage routinely available medical imaging data. The 5-year project, set...

This federal Project Grant award, titled "PRECISION TREATMENT TO PROMOTE SMOKING CESSATION AND SURVIVAL IN ONCOLOGY PATIENTS", is funded by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The $899,273 grant supports research conducted by The Washington University in St. Louis, Missouri to investigate innovative treatments that promote smoking cessation and improve survival outcomes for oncology patients. As part of...

The federal Project Grant award R01MD019690, provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), aims to reduce disparities and the burden of lung cancer among African American smokers. The $403,313 award supports a multiple-level intervention integrating lung cancer screening and smoking cessation (MILS). The key objectives are to: 1) investigate smokers' and providers' attitudes, knowledge, and experiences...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $158,290 to Kaiser Foundation Hospitals to conduct research aimed at estimating the potential for overdiagnosis of lung cancer among patients receiving lung cancer screening (LCS) care in community-based healthcare settings. The study seeks to produce a range of estimates for overdiagnosis, which is the detection of cancers through screening...

The National Cancer Institute (NCI) awarded a $639,964 Cooperative Agreement under the federal Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Wisconsin-Madison. This 2-year project aims to refine and evaluate implementation strategies to promote smoking cessation treatment referrals for clients served by the Salvation Army, a community agency with national reach. The project will partner with Salvation Army staff and clients to adapt and pilot promising...

This Project Grant award for $626,247 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to develop a tool that leverages quantitative imaging data from lung cancer screening to identify individuals at risk for undiagnosed chronic obstructive pulmonary disease (COPD). The key objectives are to: 1) Use quantitative imaging analysis of lung cancer screening CT scans to characterize COPD-related pathology and...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $697,198 to the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults ages 45-49. The key objectives of this 3-year research project are to: 1) characterize the acceptability of CRC screening in this age group and identify factors influencing screening uptake, and 2) evaluate the...

This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,958,708.00 to the University of North Carolina at Chapel Hill to conduct research on the burden and impact of false-positive results from lung cancer screening. The key objectives are to: 1) identify attitudes, knowledge, and experiences of patients and clinicians regarding false-positive screening results; 2) determine factors affecting false-positive findings; and 3)...